Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury
Phase 1/2
70
about 1.9 years
18–75
3 sites in AL, CA, TX
What this study is about
Researchers are testing whether Allogeneic Hope Biosciences Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) can help prevent progression of trauma-induced Acute Kidney Injury (AKI). The trial will last 700 days and involve approximately 70 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Allogeneic HB-adMSCs
- 2.Take Normal Saline
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence of infusion-related adverse events (AEs) or serious adverse events (SAEs)
Secondary: Number of patients with Recurrent AKI during the same hospitalization
Renal